NRSNWNeuroSense Therapeutics Ltd. Warrant
0.0446USDMkt Cap: —P/E: —3d ago
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The …
Industry Peers
Biotechnology$138.82BUSDP/E 31.9
$85.87BUSDP/E 20.5
$61.34BUSDP/E 39.8
$65.05BUSDP/E 39.6
$57.94BUSD
$45.95BUSDP/E 19.6
$44.89BUSD
$42.36BUSDP/E 67.2
$35.43BUSDP/E 32.6
$31.61BUSDP/E 41.2
$29.28BUSD
$27.47BUSD
$26.22BUSD
$25.91BUSDP/E 16.2
$20.86BUSDP/E 26.3
$19.26BUSDP/E 26.6
$16.61BUSDP/E 19.6
$16.51BUSDP/E 17.4
$15.93BUSD
$13.40BUSDP/E 17.0
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.13M $
Revenue/Share—
Last Price0.0446 USD
Fiscal Year End—
MR Quarter—
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-1.04
EPS (TTM)-0.94
EPS (Forward)—
52W Range
0.0391100% of range0.0446
52W High0.0446 USD
52W Low0.0391 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE713.14%
ROA-1082.20%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.67M $
CapEx (TTM)8.00K $
FCF Margin—
FCF Yield—
Net Debt4.00K $
Net Debt/EBITDA-0.00
Balance Sheet
Debt/Equity-0.11
Current Ratio0.31
Quick Ratio0.08
Book Value/Sh-0.0480 USD
Cash/Share0.0050 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float23.87M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta1.60
S&P 52W Chg21.00%
Avg Vol (30d)3.72K
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—